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Abstract
Pompe disease is a recessively inherited and often fatal disorder caused by the deficiency of acid a-glucosidase, an enzyme
encoded by the GAA gene and needed to break down glycogen in lysosomes. This glycogen storage disease type II has
been reported also in Swedish Lapphund dogs. Here we describe the genetic defect in canine Pompe disease and show that
three related breeds from Scandinavia carry the same mutation. The affected dogs are homozygous for the GAA c.2237G.A
mutation leading to a premature stop codon at amino acid position 746. The corresponding mutation has previously been
reported in humans and causes infantile Pompe disease in combination with a second fully deleterious mutation. The
affected dogs from both the Finnish as well as the Swedish breed mimic infantile-onset Pompe disease genetically, but also
clinico-pathologically. Therefore this canine model provides a valuable tool for preclinical studies aimed at the development
of gene therapy in Pompe disease.
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Introduction
Pompe disease, also referred to as glycogen storage disease type
II, is an autosomal recessive lysosomal storage disorder caused by a
deficiency of acid a-glucosidase (EC 3.2.1.20) in humans. The
enzyme degrades a-1,4 and a -1,6 linkages in glycogen, maltose,
and isomaltose. Deficiency of this enzyme leads to storage of
glycogen inside lysosomes and eventually also to cytoplasmic
glycogen storage. Ultimately, the accumulation of glycogen results
in tissue destruction reflected by a spectrum of clinical phenotypes
ranging from a fatal infantile form of Pompe disease to a slowly
progressive late-onset form [1,2].
Canine glycogen storage disease type II was first described in a
Lapland dog from Sweden by Mostafa in 1970 [3]. In the 1980s
researchers from the Netherlands reported clinical and morpho-
logical data of another Swedish Lapphund family affected by the
same disease [4,5]. Clinical signs and symptoms of the affected
dogs included oesophageal dilation induced vomiting, progressive
muscular weakness, loss of condition, clinical heart disease, and
myocardial hypertrophy, the severity of which required euthanasia
at about 1.5 years of age [3,4,6,7]. Pathological findings revealed
accumulation of glycogen containing vacuoles in cerebral cortex,
liver, and myocardial plus oesophageal smooth muscle, and
ultrastructural evidence of a lysosomal glycogen storage disorder
[8]. Biochemical studies demonstrated a severe deficiency of acid
a-glucosidase activity in heart, skeletal muscle and liver [9].
Furthermore, it was shown that the presence of catalytically
inactive acid a-glucosidase was the primary defect in canine
Pompe disease and, consequently, that Swedish Lapphunds
represented a homologous model of human classic infantile-
Pompe disease [5,6]. However, the primary molecular genetic
defect of canine Pompe disease has remained unknown for more
than 40 years.
In the present study we show that a recessively inherited
nonsense mutation in the acid a-glucosidase (GAA) gene causes
Pompe disease in both Swedish and Finnish Lapphunds as it does
in humans. In addition, we discovered that the same mutation
occurs in Lapponian Herders although no cases in that breed have
been reported as yet. Forty years after the initial cases were
reported our findings have finally enabled developing a genetic test
to eradicate lethal Pompe disease from the Scandinavian dog
breeds. Our study has also established affected Swedish and
Finnish Lapphunds as large animal models for the preclinical
testing of gene therapy in Pompe disease.
Materials and Methods
Study population
Four out of seven puppies from a Finnish Lapphund litter born
in 2010 were affected by slowly progressive muscle weakness and
from frequent vomiting. The affected dogs show a striking mutual
resemblance indicating a genetic disease and when clinical history
and findings were compared to the previous literature describing
inherited diseases in Lapland dogs, canine Pompe disease was
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strongly suspected [3,4,6]. We collected blood samples from two
affected dogs. Case 1 suffered from regurgitation starting at the
age of 7 months. At the age of 8 months the owner started to
notice progressive muscle weakness and at the age of 12 months
the dog started to vomit mucous. Constant panting, dysphonia and
apathetic habitus were evident at the age of 13 months. The local
veterinarian had taken radiographs of heart (age 15 months) and
thorax (age 18 months) and had performed abdominal ultrasound
examination (age 15 months) for case 1. Radiographs showed
dilatation of the esophagus and cardiac enlargement. Ultrasound
examination revealed changes in the liver. Blood chemistry
showed decreased plasma alkaline phosphatase (ALP) level and
increased alanine aminotransferase (GPT, ALAT), blood urea
nitrogen (BUN) and glucose levels and hematology results showed
increased monocyte count and increased mean platelet volume at
the age of 18 months. Case 1 is currently alive at two years of age
but is not expected to survive for very much longer.
The owner of case 2 reported that the dog gradually developed
symptoms and loss of condition at the age of 12 months. The coat
became poor quality, appetite was lost and dog was vomiting. As
the symptoms progressed the local veterinarian examined the dog
first time when she was 14 months old. Blood chemistry showed
increased plasma ALAT and aspartate aminotransferase (GOT,
ASAT) levels at the age of 15 months and they had increased
further at the age of 18 months and the dog was euthanized at the
age of 19 months. The common symptoms for both of these
siblings were vomiting of mucous, panting, dyspnea, dysphagia,
regurgitation and progressive muscle weakness. Blood was drawn
also from three healthy litter mates, both parents and 18 healthy
second degree relatives (Fig 1).
We also analyzed a DNA sample from a previously described
Swedish Lapphund with Pompe disease born in 1979 (case four
reported in [7]). This case was diagnosed at 4 months of age by
measuring low acid a-glucosidase activity in peripheral blood
leucocytes. The clinical symptoms started to appear at the age of 7
months and the dog was euthanized at the age of 14 months when
clinical disease developed.
Mutation detection and screening
The coding exons and splice junctions of the canine GAA gene
were amplified by PCR. The analysis included DNA from the two
affected Finnish Lapphunds, their dam and an unrelated healthy
8-year-old Finnish Lapphund as control. The PCR products were
purified with ExoSAP-IT kit (USB Corporation, Cleveland, Ohio)
before sequencing with an ABI Prism 3730xl DNA analyzer
(Applied Biosystems, Foster City, CA). Sequence data was
analyzed by SequencherH 5.0 software, (Gene Codes Corporation,
Ann Arbor, MI USA). The primers are available upon request.
To determine the population frequency of the newly identified
mutation we screened 95 Finnish Lapphunds, 99 Lapponian
Herders and 34 Swedish Lapphunds. Most of the Finnish
Lapphunds and Lapponian Herders were unrelated at the
grandparental level, whereas many of the Swedish Lapphunds
were related to each other. A total of 304 samples from 21 other
breeds were also screened for the mutation (Table 1).
Analysis of GAA mRNA
Blood samples from one affected (homozygous mutant) and one
unaffected (homozygous wild type) Finnish Lapphunds were
collected to PAXgene Blood RNA Tubes and total RNA was
purified using RNeasy Mini Kit (Qiagen AB, Scandinavia, Solna,
Sweden). Then mRNA was reverse transcribed to cDNA using
High Capacity RNA-to-cDNA Kit (Applied Biosystems, Foster
City, CA). Part of the GAA cDNA was sequenced using exon-
specific primers (available upon request).
Ethics statement
All samples were from privately owned pets and we obtained
consent from the owners of the dogs involved in our study. We also
obtained permission for blood sampling from the Animal Ethics
Committee (ESLH-2009-07827/Ym-23), The State Provincial
Office of Southern Finland, P.O. B150, 13101 Ha¨meenlinna.
Results
As part of our canine disease genomics program, we became
interested in identifying the molecular basis of Pompe disease in
dogs when we encountered a Finnish Lapphund litter with four
affected dogs. Their symptoms and their clinical findings were
consistent with those previously described in four Swedish
Lapphunds with Pompe disease [3,4,7]. As a first action, we
collected blood samples from two of the four affected Finnish dogs,
from three of their unaffected littermates and from their parents
for the purpose of DNA extraction.
Exonic sequencing of the canine GAA gene revealed a
c.2237G.A change, compared to the reference sequence RefSeq
XM_845556.2, that results in a premature stop codon p.W746* in
the 15th coding exon. The nucleotide numbering reflects the
cDNA numbering with +1 corresponding to the A of the ATG
initiation codon; the amino acid numbering is according to
XP_850649.1. The p.W746* mutation truncates the last 206
amino acids (,22% of the protein) of the canine acid a-
glucosidase and its effect is very severe according to the Pompe
Disease Mutation Database at www.pompecenter.nl. The two
affected Finnish Lapphund littermates were both homozygous for
the mutation, their parents were both heterozygous, two of their
three healthy littermates were heterozygous and one was
homozygous wild type (Fig. 1). In addition, ten synonymous
coding variants and seven intronic variants were detected in GAA
gene but none of them segregated with the disease.
It then became interesting to investigate if the Swedish
Lapphunds that had been described back in the 1960s and
1970s, when DNA analysis was not yet possible, had the same or
another Pompe disease mutation. Fortunately, a cell line
established in those days from the tong tissue was successfully
retrieved from storage in liquid nitrogen and could serve as a DNA
source. Thereby, we were able to establish that one of the
originally described Swedish Lapphunds with Pompe disease was
also homozygous for the same c.2237G.A mutation.
We then aimed to screen the current Finnish and Swedish
Lapphund populations, the Lapponian Herders and 22 other
breeds for the occurrence of the c.2237G.A mutation. This study
revealed that the mutation is present only in two Scandinavian
breeds: 5% (5/95) of Finnish Lapphunds and 2% (2/99) of
Lapponian Herders carry the mutation. The cohort of 34 Swedish
Lapphunds did not contain any carriers.
Sequencing of the GAA mRNA from homozygous mutant
Pompe case and from wild type healthy control revealed that the
mutated gene is transcribed into mRNA suggesting that it does not
lead to large-scale nonsense-mediated RNA decay (data not
shown). This is consistent with the previous study showing that the
mutated GAA protein is also present in the affected dogs, although
in an inactive form [6].
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Discussion
Pompe disease is an autosomal recessive disorder in humans
caused by mutations in the GAA gene (OMIM #232300, [10,11]).
Acid a-glucosidase is encoded by the GAA gene. It is essential for
the degradation of glygogen to glucose in lysosomes. Over 300
potentially pathogenic GAA mutations have been identified in
human patients (www.pompecenter.nl). Human patients are often
compound heterozygotes. A combination of two mutated alleles
deleting the enzymatic function completely results in infantile-
onset Pompe disease. Different combinations of other mutations in
the GAA gene affect GAA activity and modify the onset and
progression of the disease. However, at present, it is not possible to
predict in all cases the clinical course based on genotype alone
[12].
Besides humans, Pompe disease has also been reported in other
species including cattle (OMIA 000419-9913, [13,14]), Japanese
quails (OMIA 000419-93934, [15]), cats (OMIA 000419-9685,
[16]), sheep (OMIA 000419-9940,[17]) and dogs (OMIA 000419-
9615, [3,4]). Three breed-specific mutations in bovine GAA gene
all causing a premature stop codon have been identified in
Brahman and Beef Shorthorn cattle [18]. So far no mutations
have been identified in cats, quails or sheep with Pompe disease.
Until now, the genetic defect underlying canine Pompe disease has
also remained unknown.
The clinical, pathological and biochemical characteristics of
classic infantile Pompe disease in humans and dogs resemble each
other very well [6–8]. The pathogenesis in both species implies the
total absence of acid a-glucosidase activity, generalized glycogen
storage leading to progressive muscular weakness, cardiac
hypertrophy, cardio-respiratory failure and death. A finding
unique to the disease in dogs is the megaoesophagus and its
associated symptoms of regurgitation and vomiting [8]. With
respect to this manifestation, the difference between humans and
dogs might be related to their different posture. Swallowing
difficulties are amongst the clinical manifestations of Pompe
disease in humans, but are neither associated with dilatation of the
oesophagus nor do they lead to vomiting.
The p.W746* nonsense mutation was first reported in
combination with a second fully deleterious mutation
(c.2758_2775dup) in a patient with infantile onset Pompe disease
[19]. Later, four Italian infants were reported to carry this
mutation in four different heteroallelic combinations with either
c.525delT, c.670C.T, c.1655T.C, or c.2481+102_2646+31del
[20–22]. In addition, 9/40 Italian patients with late onset forms of
Pompe patients were identified as carriers of the p.W746*
mutation. All of them had the most common leaky splice variant
c.-32-13T.G as second mutation [23]. W746* has also been
reported in heteroallelic combination with the less severe P285S
variant and was in that case associated with late-onset disease [24].
The fact that W746* was rather frequently seen in humans and is
now also found in dogs suggests that the chromosomal region
around c.2237G is a mutation hotspot. The listing of c.2236T.G,
c.2237G.C, c.2238G.C, c.2238G.A as other pathogenic
mutations in human Pompe disease supports this view (www.
pompecenter.nl).
Figure 1. The pedigree of the Finnish Lapphunds affected with Pompe disease. Four puppies suffered similar symptoms and two of them
(arrows) were available for genetic studies. All five mutation carriers that were identified by screening of 95 healthy Finnish Lapphunds could be
traced back to the same pedigree. The GAA c.2237G.A genotypes of the studied dogs are shown below the gender symbol.
doi:10.1371/journal.pone.0056825.g001
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Although the affected Swedish Lapphund born in 1979 was
homozygous for the mutation and original reports indicate that
there have been several cases among Swedish Lapphunds in those
days [3–7], we were not able to identify any carriers from the
current dogs of this breed. This might be due to too small sample
size. It is also possible that the rigorous breeding program has
eliminated the carriers from the modern Swedish Lapphunds. It is
also worth noting that we identified carriers from Lapponian
Herders although no affected cases have been reported in this
breed.
The canine p.W746* mutation is shared exclusively among the
three closely related breeds from Lapland reflecting a founder
effect. The Finnish and Swedish Lapphunds and Lapponian
Herders are all descended from the guarding and reindeer herding
dogs of Sa´mi people from northern Scandinavia [25]. The
Swedish Lapphund is one of the native Swedish breeds and the
other two breeds originate from Finland. Lapphunds are very
similar; the biggest difference is the coat color. In Swedish
Lapphunds, only black color is accepted whereas in the Finnish
Lapphunds all colors are allowed for breeding. Finnish Lapphund
and Lapponian Herder were separated in the 1960s on the basis of
their coat length [25]. Nowadays these two breeds differ also in
overall shape.
Though Pompe disease was described already in the 1960s–
1980s in Swedish Lapphunds, its existence in Finnish Lapphunds
had not previously been reported by breeders. As far as we know,
these Finnish Lapphund dogs are the first correctly diagnosed
cases in Finland. Difficulties in diagnosing Pompe disease in
Lapphunds might have caused diagnostic delay, but the moder-
ately low mutation frequency in the Finnish Lapphund breed and
the pattern of autosomal recessive inheritance appear contributing
factors. Our study enables the development of a genetic test for
these Scandinavian dog breeds so that this rare but fatal disease
can now be eradicated.
Enzyme replacement therapy (ERT) is currently the only
effective treatment for human Pompe disease. ERT has been
shown to improve ventilator-free survival in patients with infantile-
onset Pompe disease. Recent studies indicate that also children
and adults benefit from treatment [26,27]. However, the present
form of ERT does not provide a total cure. Therefore, the
challenge of improving ERT or introducing alternative therapeu-
tic interventions remains. Given the current promising achieve-
ments in the field of gene therapy this approach deserves serious
investigation also for treatment of Pompe disease. Being large and
well described animal models, the Finnish and Swedish Lap-
phunds could be instrumental in these new developments.
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